Health
GLP-1 Lawsuit & News Tracker: Ozempic, Wegovy, Mounjaro, Zepbound, Trulicity
The GLP-1 family of drugs might be the biggest thing since AI. There have been unexpected benefits and about as many unexpected problems.
It's a little hard to define but for our purposes, this section is all about consumer protection -- regulatory actions, laws, class actions and anything that helps take the edge off.
Health
The GLP-1 family of drugs might be the biggest thing since AI. There have been unexpected benefits and about as many unexpected problems.
Consumer Protection
Regulators allege Hopper promised "no hidden fees" while automatically adding optional charges for tips and VIP customer support unless consumers found and deselected them.
Health
Senior feds terminate criminal investigation of Abbott Labs baby-formula contamination.
Money
A new class-action lawsuit says fuel-pricing software turned old-fashioned price fixing into an automated system
Consumer Protection
The CFPB says it is cleaning up an overloaded complaint portal but consumer advocates are skeptical.
Consumer Protection
Americans say they are spending more time, money and emotional energy trying to solve routine problems with airlines, banks, retailers, telecoms, health insurers and delivery companies.
Consumer Protection
The state’s new enforcement statement takes aim at surprise charges, vague add-ons, dark patterns and fees that provide little or no value.
Consumer Protection
A proposed California class action claims Temu used deceptive email offers to get consumers to click through to its website so it could collect personal information about them.
Consumer Protection
How "deposit alternatives" work — and what they can do to your credit
Consumer Protection
The overlap between scams, auto issues, housing, healthcare and debt problems is striking and tells a broader affordability-and-fraud story.
Health
Regulators say some firms falsely implied their products were equivalent to FDA-approved medications such as Wegovy, Ozempic, Zepbound, and Mounjaro. The U.S. Food and Drug Administration has intensified its campaign against the booming online weight-loss drug industry, issuing warning letters to 25 telehealth companies that allegedly made
Money
Growing awareness of "surveillance pricing" lands a prominent defendant